GlassScriptPhysician profile
Robert Farivar
NPI 1588866354
$140,312.17
in general payments reported to CMS, 2019-2025
20 companies · $23K in 2025
The $23K reported for 2025 was more than what 94% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,631 · 2020: $14K · 2021: $10K · 2022: $10K · 2023: $46K · 2024: $35K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $59K · Travel and Lodging: $20K · Honoraria: $12K · Food and Beverage: $9,044 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $58,517.00 |
| Travel and Lodging | $19,586.83 |
| Honoraria | $12,350.00 |
| Food and Beverage | $9,044.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,725.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $64,121.97 | 2020-2025 | Mitris Resilia Mitral Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Inspiris Resilia Aortic Valve |
| Abiomed | $29,750.15 | 2021-2025 | Impella |
| Abbott Laboratories | $24,526.88 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Atricure, INC. | $10,852.36 | 2021-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atriclip Laa Exclusion System |
| Bolton Medical INC | $4,994.33 | 2024-2025 | Treo Abdominal Stent-Graft System, Thoraflex Hybrid, Relay Thoracic Stent-Graft With Plus Delivery System |
| Zimmer Biomet Holdings, INC. | $3,014.13 | 2019-2024 | Sternalock Blu System, Sternalock 360 System |
| Medtronic, INC. | $1,558.62 | 2021-2025 | Vitalflow Console, Ligasure |
| Biomerieux INC | $590.50 | 2024-2025 | Vidas Nephrocheck |
| Medtronic Vascular, INC. | $197.48 | 2020 | |
| Kls-Martin L.P. | $178.39 | 2021-2023 | |
| Artivion, INC. | $177.21 | 2019-2021 | |
| La Jolla Pharmaceutical Company | $122.71 | 2022 | |
| Angiodynamics, INC. | $70.23 | 2019-2021 | |
| Ethicon US, LLC | $46.40 | 2019 | |
| Stryker Corporation | $34.41 | 2025 | Spy-Phi System |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lsi Solutions INC | $32.94 | 2024 | Cor-Knot |
| Getinge USA Sales, LLC | $19.91 | 2023 | Vasoview Hemopro 2 |
| Shockwave Medical, INC | $12.49 | 2019 | |
| Terumo Cardiovascular Systems Corporation | $11.06 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Farivar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.